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Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia after Alzheimer’s disease. A
high-ranking candidate to become a diagnostic marker for a major pathological subtype of FTLD is the transactive
response DNA binding protein of 43 kDa (TDP-43). The main objective is to elucidate which antibodies are specific
for pathological TDP-43, with special interest in its modified isoforms. Indeed, TDP-43 has been shown to be
hyperphosphorylated and truncated in disease. A secondary objective is to review existing immunoassays that
quantify TDP-43 in biofluids. A systematic review of literature was performed by searching PubMed and Web of
Science using predefined keywords. Of considered research papers the methods section was reviewed to select
publications that enabled us to answer our learning objective. After quality assessment, antibody characteristics
and related outcomes were extracted. We identified a series of well-characterized antibodies based on a scoring
system that assessed the ability of each antibody to detect TDP-43 pathology. A selection of 29 unique antibodies
was made comprising 10 high-ranking antibodies which were reported multiple times to detect TDP-43 pathology
in both immunostaining and immunoblotting experiments and 19 additional antibodies which detected TDP-43
pathology but were only scored once. This systematic review provides an overview of antibodies that are reported to
detect pathological TDP-43. These antibodies can be used in future studies of TDP-43 proteinopathies. Additionally,
selected antibodies hold the potential to be used in the development of novel immunoassays for the quantification
of TDP-43 in biofluids, as a possible biomarker for FTLD-TDP.
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Frontotemporal lobar degeneration (FTLD) is the pri-
mary cause of early onset dementia after Alzheimer’s
disease (AD) [1]. Worldwide prevalence of FTLD is
underestimated due to difficult diagnosis complicated by
clinical, neuropathological and genetic heterogeneity
[2-5]. FTLD is clinically subdivided into behavioral vari-
ant frontotemporal dementia (bvFTD) [6] and language
variant primary progressive aphasia (PPA) which in its
turn comprises three variants [7]. The most common
genetic etiologies resulting in FTLD include mutations* Correspondence: sebastiaan.engelborghs@uantwerpen.be
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unless otherwise stated.in tau (MAPT) and progranulin genes (GRN) and a
repeat expansion in C9orf72 [8-13]. Molecular path-
ologies underlying FTLD include aggregation from tau
(FTLD-tau) or fused-in-sarcoma proteins (FTLD-FUS),
accounting for approximately 45% and <5% of patients
respectively [14]. The major pathological subtype, ac-
counting for approximately 50% of FTLD population, is
FTLD-TDP where patients have brain inclusions of
transactive response DNA-binding protein of 43 kDa
(TDP-43) [15,16]. Under physiological conditions, TDP-43
is a predominantly nuclear protein and its role in transcrip-
tion and splicing regulation is well characterized [17]. In
FTLD-TDP, TDP-43 is redistributed to the cytoplasm
where it forms intraneuronal inclusions. This leads to an
apparent loss of nuclear TDP-43 function, while theal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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more, aggregation of TDP-43 is also characteristic for
amyotrophic lateral sclerosis (ALS) [16], and clinical and
genetic overlap between both disorders has corroborated
their association in an FTLD-ALS spectrum [20]. Note-
worthy, other neurodegenerative disorders can present
with TDP-43 pathology as secondary feature, and this is
the case in 20-50% of patients with AD and related tauopa-
thies [14,21]. A comorbid TDP-43 pathology is reported to
worsen neurodegeneration independently of AD pathology,
leading to a more severe clinical presentation of dementia
[22].
While mutations in a specific gene induce an associ-
ated molecular pathology, no strict relationship exists
between clinical FTLD subtype and underlying proteino-
pathy [15,23]. Indeed, clinical symptoms rather reflect
affected brain regions, which is especially exemplified in
the heterogeneity of clinical FTLD. Moreover, it should
be noted that up to 25% of clinical FTLD is actually due
to atypical presentation of AD pathology [14,24]. The
two-way clinicopathological association between FTLD
(−TDP) and AD shows there is an urgent need for
biomarkers that allow early and differential diagnosis
of FTLD. A promising approach is quantification of
disease-specific biochemical markers present in biofluids
(cerebrospinal fluid (CSF) and blood) [23]. At present,
well-characterized and validated diagnostic markers
specific to FTLD pathology do not exist, with the excep-
tion of decreased progranulin concentrations for GRN
mutation-related FTLD, a subgroup of FTLD-TDP
[25,26]. A high-ranking candidate to become a bio-
marker for all FTLD-TDP patients is TDP-43 itself.
Because of low absolute levels, quantitative analysis
of TDP-43 in biofluids will demand a very sensitive
immunoassay, preferably specific for pathological TDP-43
[27]. The TDP-43 protein comprises two RNA-recognitionFigure 1 Selected antibodies mapped to the TDP-43 protein. Antibodi
secondary selection are marked in grey. Asterisks indicate phosphorylation-
considered “standard” when studying TDP-43. NLS = nuclear localization sigmotives (RRM1-&2) and a glycine-rich C-terminal domain
(Figure 1) [17,28]. Pathological aggregation of TDP-43 is
regulated by both N-terminal and C-terminal regions,
but also includes modifications like truncation, ubiquiti-
nation and phosphorylation [16,29-32]. Reported trun-
cation sites are located inside the RRM2 and include
Arg208, Asp218 and Asp247 [33-35] while major phos-
phorylation sites are serine residues located near the
C-terminal end of TDP-43 [32,36].
The primary objective of this systematic review is to
identify which antibodies have previously been described
to detect TDP-43 pathology. These antibodies are
expected to be suitable for defining the characteristic
profile of pathological TDP-43 in human brain and
biofluids, using immunostaining and immunoblotting.
Additionally, antibodies specific for TDP-43 pathology
hold potential to be used in immunoassays for quan-
tification of TDP-43 and its pathological isoforms in
biofluids. In this regard, a secondary objective is to re-
view existing immunoassays with reference to specific
antibody pairs.Methods
A systematic review of existing literature was performed
by searching PubMed and Web of Science using the pre-
defined keywords “TDP 43” and variations like “transac-
tive response DNA binding protein” or “TAR DNA
binding protein” in publication title, and keywords
indicating the use of antibodies (such as “antibody”,
“immunoblot”, “immunohistochemistry” “immunoassay”
or “ELISA” or, to broaden the search, “aggregate” or
“inclusion”) in title or abstract for PubMed and as
topic for Web of Science. Only original research papers
published between 06/10/2006 (first report of TDP-43 as
pathological protein in disease [16]) and 31/12/2014 werees from the primary selection are marked in black, antibodies from the
dependent antibodies. Bold italic antibodies are those which are
nal, NES = nuclear export signal, RRM = RNA-recognition motive.
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section was checked to select papers able to answer our
learning objective.
Quality assessment
Papers that did not report the use of an antibody di-
rected at TDP-43 (e.g. genetics based) were excluded.
Because the aim was to assess specificity of antibodies
with applicability to human disease, papers using yeast,
C. elegans or Drosophila as model organism were ex-
cluded. From relevant papers following data was ex-
tracted and tabulated: antibody characteristics (i.e. name,
epitope, manufacturer, clonality, species), used immuno-
assays, assessed target (e.g. organism, cell line, biofluid,
tissue), relevant immunoassay outcomes (i.e. description
of staining, biochemical profile, TDP-43 concentration)
and study strengths and limitations. For completeness of
the systematic review, antibodies were characterized
thoroughly by consulting available published data, manu-
facturer websites and corresponding authors. This allowed
identification of epitopes at amino acid (AA) level [37,38]
and identification of monoclonal clone numbers.
When provided with enough information to identify the
exact antibody (known name, epitope, manufacturer,
clonality and species), published results were scored
for each paper that used the same antibody both in
immunostaining and immunoblotting experiments. The
scoring is a basic “Yes/No” system indicating if an
antibody reacts with pathological TDP-43 in the reported
setup or not. For staining, a positive score signifies
visualization of any form of pathological inclusions, while
for blotting a positive score responds to the presence of
high molecular weight smears and/or distinct C-terminal
fragments [39,40]. A negative score was given when there
was no reactivity or only nuclear TDP-43 of 43 kDa was
described as immunoassay result. Scoring was performed
independently by two researchers (JG, EVM) and discrep-
ancies (<10%) were rescored by consensus.
From tabulated scores, a primary selection of anti-
bodies was listed based on having a positive score on
one or both immunoassays multiple times. A secondary
selection was made from antibodies that scored positive
on one or both immunoassays only once.
Results
Search results
The initial search resulted in a total of 671 publications,
including 490 found in both databases. After selection
of relevant English research papers 409 publications
remained. These publications report the use of 833
antibodies (approximately 100 unique) from which the
characteristics were extracted. Relevant immunoassay
outcomes were scored for each well-characterized anti-
body (506 of 833 reports, 74 unique antibodies). In 132of these reports both immunostaining and immunoblot-
ting were performed with the same antibody, leaving a
total of 38 different antibodies for further assessment.
Main results
The primary selection, representing antibodies capable
of detecting TDP-43 pathology with both immunoassays,
includes 9 unique antibodies reported 62 times with a
double positive score and 33 times with a single positive
score. One additional antibody only has multiple reports
with a single positive score (Table 1). The secondary se-
lection consists of 19 unique antibodies (Additional file 1:
Table S1).
A detailed look at the 10 highest-ranking antibodies
(Table 1, Figure 1) shows that one antibody has two
known epitopes, recognizing both the N-terminal region
and the RRM2. Two other antibodies are directed at
the RRM2, and three have an epitope located in the
C-terminal region of TDP-43. The remaining four
antibodies also map in the C-terminal region but are
specific for the phosphorylated serine residues. A majority
of antibodies are polyclonal (n = 7; monoclonal: n = 3),
and most antibodies have been reported first as in-house
generated (n = 7).
Regarding the supplementary 19 antibodies that have
shown potential to detect TDP-43 (Additional file 1:
Table S1, Figure 1), four have an epitope located in the
N-terminal region. The other antibodies again map in
the RRM2 (n = 2) or the C-terminal region (n = 12, of
which six phosphorylation-specific). One antibody can-
not be categorized accordingly, as its immunogen overlaps
the RRM2 and C-terminal region. Other characteristics of
the secondary selection are a balanced distribution of
clonality (monoclonal: n = 9; polyclonal: n = 10) and a
striking 16 antibodies originally in-house generated.
An interesting consideration in the context of this re-
view is the reported use of enzyme-linked immunosorb-
ent assays (ELISAs) to quantify TDP-43. A total of 10
publications are available, describing 12 assays [41-50].
However, only five different antibody pairs (i.e. five dif-
ferent assays) have been used, and two of these are com-
mercially available kits (Table 2). Noteworthy, merely a
single assay has been reported more than once. Evalu-
ation of antibody pairs shows that three assays are com-
pletely made up of antibodies from the selection, which
implies they are very specific for their respective targets.
Regarding epitope specificity (and therefore ELISA
target), two reported ELISAs, including the most com-
monly described one, use an antibody directed at the
RRM2 of TDP-43 together with the antibody having epi-
topes in the N-terminal region and the RRM2. Conse-
quently, these assays will quantify full-length TDP-43
and maybe, depending on the truncation site, some
C-terminal fragments. Two other ELISAs quantify
Table 1 List of antibodies that are selected based on their ability to detect TDP-43 pathology, reported multiple times












1D3 (pS409/410, AA 403–414/P) Millipore/Neumann 2009 mono rat 3 - - 3
TIP-PTD-P05 (pS403/404;
AA 398–408/P)
Cosmo Bio/Hasegawa 2008 poly rabbit 5 1 - 6
TIP-PTD-M01 (pS409/410;
AA 405–414/P)
Cosmo Bio/Inukai 2008 mono mouse 7 2 - 9
TIP-PTD-P01&-P02 (pS409/410;
AA 405–414/P)
Cosmo Bio/Hasegawa 2008 poly rabbit 12 5 - 17
1039C/C-t TDP-43 (AA 394–414/P) Igaz 2008 poly rabbit 5 2 2 9
10782 (AA 203–209 and AA near
N-terminus/R)
ProteinTech poly rabbit 14 9 2 25
2E2-D3 (AA 205–222/R) Abnova, Novus, Abcam, etc. mono mouse 12 8 4 24
12892 (AA 288–414/R) ProteinTech poly rabbit 3 2 1 6
TIP-TD-P09 (AA 405–414/P) Cosmo Bio/Hasegawa 2008 poly rabbit 1 2 - 3
MC2085 (AA 220–227/P) Zhang 2009 poly rabbit - 2 - 2
Antibodies are ordered by percentage of double positive reports. Immunogen is depicted as P = peptide immunogen or R = recombinant protein immunogen.
Bold italic antibodies are those which are considered “standard” when studying TDP-43.
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antibody directed at the RRM2 (or at an unknown
epitope) with an antibody recognizing the C-terminally
located phosphorylated serine residues. Again, there is a
possibility for the detection of some C-terminal frag-
ments that have undergone phosphorylation depending
on the truncation site within the RRM2. The last re-
ported ELISA is specifically directed at the C-terminal
region, and will therefore quantify all C-terminal frag-
ments. Looking at the antibody specificity, it is reason-
able to assume this assay also quantifies full-length
TDP-43, while phosphorylated C-terminal fragmentsTable 2 Overview of existing ELISAs, with detailed informatio
Antibody (Epitope) Manufacturer/First report Clona
Capture 2E2-D3 (AA 205–222) Abnova, Novus, Abcam, etc. mono
Detection 10782 (AA 203–209 and
AA near N-terminus)
ProteinTech poly
Capture 2E2-D3 (AA 205–222) Abnova, Novus, Abcam, etc. mono
Detection TIP-PTD-P02 (pS409/410,
AA 405–414)
Cosmo Bio/Hasegawa 2008 poly
Capture 10782 (AA 203–209 and
AA near N-terminus)
ProteinTech poly
Detection 60019 (AA 203–209) ProteinTech mono
Capture not specifieda EIAab poly
Detection SAB4200223 (pS409)a Sigma poly




aInformation provided by kit manufacturer, confirming published assay details. Abb
phosphorylated C-terminal fragments. Bold italic antibodies are those which are coare more than likely excluded. However, this assay
has only been reported with data on cell lysates and
brain homogenates and has not been used in bio-
fluids, let alone in a patient study [47].
Apart from aforementioned publications using ELISAs,
only three other reports were found where TDP-43 is de-
tected in biofluids, by means of an immunoblot [51-53].
Discussion
This review was undertaken to identify the most suitable
antibodies for future research of TDP-43, while evaluat-
ing ELISAs already used for its quantification. As muchn about used antibodies
lity Species Target detected Times reported References
mouse • full length TDP-43 8 [41-45,48-50]
rabbit • (some CTFs)
mouse • pTDP-43 1 [42]
rabbit • (some pCTFs)
rabbit • full-length TDP-43 1 [46]
mouse
rabbit • pTDP-43 1 [46]
rabbit • (pCTFs)
mouse • (full length TDP-43) 1 [47]
rabbit • CTFs
• (pCTFs)
reviations: CTFs, C-terminal fragments; pTDP-43, phosphorylated TDP-43; pCTFs,
nsidered “standard” when studying TDP-43.
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reported to detect TDP-43 pathology. In contrast, only
five different ELISAs have been published and their anti-
body combinations leave room for improvement.
The majority of antibodies in the final selection are
characterized by an epitope in the C-terminal region,
and many of them are specific for phosphorylated TDP-
43. These findings are expected, since C-terminal trun-
cation and phosphorylation are hallmarks of aggregated
TDP-43 in disease [16,30,32]. However, the observed re-
sult is not bidirectional, as several antibodies directed at
pathological isoforms do not specifically reflect TDP-43
pathology. This is the case for those antibodies that only
obtained double negative scores, but is probably also the
case for some antibodies in the secondary selection. The
fact that certain antibodies have only been used once
has two possible reasons. First, for “older” antibodies in
the list, it might be an indication for their lack of sensi-
tivity and specificity (false positives). This is a feature
addressed by groups generating in-house antibodies
themselves, who make a selection of antibodies to use
for further research after internal validation [32,36].
With this in mind, it is not unlikely that antibodies of
lower affinity are also generated and made available by
commercial companies. Alternatively, “recent” antibodies
in the secondary selection have not yet had the chance
to be used multiple times (false negatives). However, also
in these cases there can be antibodies that will not be
pursued further by the manufacturing group [47,54]. Of
note, the occurrence of false negatives because of a lack
of replication studies also applies to antibodies that
have not been used in both immunoassays in one
publication and therefore were not included in the
scored antibody list.
Another reason for false positive and false negative re-
sults is the fact that antibodies are always used in a very
specific setup. For example, antibodies used for studying
exogenous expressed C-terminal fragments are not ne-
cessarily successful in detecting pathological TDP-43 in
patients. Conversely, when antibodies are used to study
patients without suspected TDP-43 pathology it is
understandable that they will indeed not detect path-
ology. These remarks are supported by the fact that
many antibodies in the primary selection do not consist-
ently have a double positive score, and some are even
reported with a double negative score. Finally, there is
the potential occurrence of biased results, since three
antibodies are considered “standard” antibodies for
studying TDP-43 proteinopathies, and are thus widely
used. These antibodies are 10782 (ProteinTech), 2E2-D3
(available from different manufacturers) and TIP-PTD-
P01&-P02 (Cosmo Bio) [38,55]. This assumption is
reflected in the systematic review, as together they ac-
count for almost half the reports using a well-characterizedantibody. 10782 (115/506 reports, 22.7%) and 2E2-D3
(68/506 reports, 13.4%) have been available since the
beginning of TDP-43 studies [16,56]. TIP-PTD-P01&-P02
(68/506 reports, 13.4%) was first reported by the group
which generated it, in a publication initiating the branch
of research on phosphorylated TDP-43 [32]. Despite being
commonly used, these antibodies are not necessarily the
best options when studying TDP-43 pathology. 10782 only
has a double positive score in 56.0% of its scored reports
(14/25). However, it has been successful in the develop-
ment of an ELISA both as capture or detection antibody,
and is capable of immunoprecipitation. These facts prove
that the antibody has the desired affinity for total TDP-43.
2E2-D3 is reported with a double positive score in 50.0%
of its scored reports (12/24), and this antibody has also
been successfully used in ELISAs and immunoprecipita-
tion. Moreover, its specificity for human TDP-43 makes
it very suitable in research of TDP-43 in transgenic ani-
mal models [38]. Nevertheless, when looking to study
pathological TDP-43, TIP-PTD-P01&-P02 has a better
track record, with 70.6% of its scored reports having a
double positive score (12/17).
A final point of discussion when selecting antibodies
to study TDP-43 is the use of commercially available
antibodies or the generation of antibodies in-house. Des-
pite favorable antigenicity profiling of TDP-43, only a
few well-characterized antibodies within the systematic
search are available from companies (n = 24, Additional
file 1: Table S2). Most of these antibodies are polyclonal
(n = 19) of which 15 are directed at the C-terminal re-
gion (including five phosphorylation-specific). Of the
well-characterized commercial monoclonal antibodies
one maps in the N-terminal region, two recognize
epitopes in the RRM2 of TDP-43 and two are
phosphorylation-dependent. The lack of available anti-
bodies specific for pathology has stimulated the gener-
ation of novel antibodies. A number of groups have been
successful using this approach and five in-house gener-
ated antibodies are now also commercially available
[32,36,57]. However, many more have only been used a
few times by the original group, in collaborative efforts
or have not been used again after their first report
[30,47,54,58-64]. Noteworthy, most high-ranking anti-
bodies in the selection with an epitope directed at patho-
logically modified TDP-43 are originally in-house
generated. From a research perspective this is a logical
starting point when undertaking the production of anti-
bodies, as these antibodies are more likely to be suitable
for the study of TDP-43 pathology. As a side note, in-
house generation of antibodies requires the use of either
peptide immunogens or recombinant protein immuno-
gens. In practice, only peptides can be used to obtain
antibodies specific for major protein modifications. In-
deed, all reported antibodies directed at phosphorylated
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immunogen. The predominance of antibodies generated
with peptide antigens is also related to the propensity of
recombinant TDP-43 protein to aggregate, which is es-
pecially the case for C-terminal fragments [33]. With
regard to ELISA development, antibodies generated with
recombinant protein antigens are more than suitable
when developing an ELISA for whole-target quantifica-
tion, but when looking to quantify different isoforms of
one protein optimal results are to be expected with pep-
tide antigens.
As far as reported immunoassays detecting TDP-43
and its isoforms in biofluids go, it is clear that improve-
ments can and should be made. Merely looking at used
combinations of antibodies, previous ELISAs were devel-
oped to reflect either total TDP-43 or phosphorylated
TDP-43 levels. However, none of these assays accounted
for the presence of C-terminal fragments, as these
may have been quantified together with full-length
(phosphorylated) TDP-43. To utilize TDP-43 as an
effective biomarker applicable for human TDP-43
proteinopathies, it is very likely that all isoforms of
TDP-43 will need to be quantified separately. From
this point of view, the ELISA reported by Kwong et al.
[47] is already a step in the right direction, although it
will probably still detect full-length TDP-43 together with
C-terminal fragments. To solely quantify full-length
TDP-43 a less ambiguous combination of antibodies
should be used, that is certain to exclude any C-terminal
fragments. The same requirement applies for quantifica-
tion of phosphorylated full-length TDP-43 without inter-
ference from phosphorylated C-terminal fragments.
Although lone detection of C-terminal fragments seems
difficult, a few antibodies are reported to be specific
enough to potentially achieve this [47,60], and further ef-
forts should be undertaken to quantify this pathological
isoform. When this is made possible, an assay specific for
phosphorylated C-terminal fragments can also be devel-
oped, completing the spectrum of TDP-43 pathology.
In the context of this systematic review it is necessary
to comment on the recent publication by Feneberg et al.
describing a limited role for TDP-43 as a diagnostic tool
[52]. The main finding of this publication is that TDP-43
present in CSF is mainly blood-derived. This is based on
an immunoblot analysis, which shows that the concen-
tration of TDP-43 in blood is 200 times higher than that
in CSF. Based on published ELISAs it is difficult to com-
ment on the comparison of TDP-43 levels between CSF
and plasma. Only one study has quantified TDP-43 in
CSF and plasma of the same patients and here only rela-
tive concentrations are reported, so no conclusion can
be made with regard to blood/CSF ratio [46]. However,
the claim that TDP-43 is mainly blood-derived and is
therefore of minor importance as diagnostic tool is weak.Other studies on biomarker levels measured in paired
blood and CSF samples demonstrate that correlations
are more complex than anticipated. For example, though
progranulin is much more abundant in plasma and its
plasma and CSF levels correlate, plasma progranulin
levels can only account for a very small part of the vari-
ability of CSF progranulin levels [65].
A final remark, which is also supported by Feneberg
et al. [52], is that exosomes present in CSF may contain
TDP-43 which is not blood-derived and may therefore
be more suitable to reflect TDP-43 pathology. Thus,
even if it is confirmed that TDP-43 in CSF has limited
diagnostic value, this would only result in the adjust-
ment of future immunoassays to another target, namely
exosome preparations. But first, further evidence needs
to be gathered by independent researchers before this
assumption can be considered valid.
Potential limitations of the study
In order to make sure selected antibodies can be used in
all future studies of TDP-43 proteinopathies, regardless
of preferred immunoassay, we decided to score only
those antibodies used for both immunostaining and im-
munoblotting in the same publication. As this might be
a methodological limitation of the review process, we
performed the same analysis on the entire dataset which
resulted in a comparable selection, including all 10
highest-ranking antibodies. Another possible limitation
is the use of a scoring system to generalize descriptive re-
sults reported with different antibodies, under different ex-
perimental conditions. However, using a scoring system is
indispensable in order to compare antibodies across stud-
ies, and all immunoassay outcomes were independently
scored by two researchers to ensure reliable categorization.
Conclusions
This systematic review provides an overview of anti-
bodies reported to detect TDP-43 pathology. These anti-
bodies can be used in animal models and patient studies
of TDP-43 proteinopathies, such as FTLD. Thus, re-
searchers studying these disorders can choose highly
sensitive and specific antibodies most suitable for their
objective based on this review. Antibodies from the
primary selection have consistently proven their func-
tionality in detecting pathological TDP-43 in both im-
munostaining and immunoblotting. Antibodies from the
secondary selection have the potential to detect TDP-43,
but validation of their results is necessary before conclu-
sions can be made regarding their future use. Addition-
ally, high-ranking antibodies are leading candidates
when selecting an antibody pair in future development
of novel quantitative immunoassays for TDP-43 in bio-
fluids or exosome preparations, as a possible biomarker
for FTLD-TDP.
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